Literature DB >> 24648800

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.

Ji-Hye Lee1, Mee-Hye Oh1, Jae-Seok Park2, Gyoung-Jae Na2, Hye-Wook Gil2, Jong-Oh Yang2, Eun-Young Lee2, Sae-Yong Hong2.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to investigate the expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1 on podocytes in immunoglobulin A (IgA) glomerulonephritis (GN).
METHODS: Renal biopsy specimens from 52 IgA GN patients were deparaffinized and subjected to immunohistochemical staining for uPA, PAI-1, and uPAR. The biopsies were classified into three groups according to the expression of uPA and uPAR on podocytes: uPA, uPAR, and a negative group. The prevalences of the variables of the Oxford classification for IgA GN were compared among the groups.
RESULTS: On podocytes, uPA was positive in 11 cases and uPAR was positive in 38 cases; by contrast, PAI-1 was negative in all cases. Expression of both uPA and uPAR on podocytes was less frequently accompanied by tubulointerstitial fibrosis.
CONCLUSIONS: Our results suggest a possible protective effect of podocyte uPA/uPAR expression against interstitial fibrosis.

Entities:  

Keywords:  Glomerulonephritis, IGA; Plasminogen activator inhibitor 1; Receptors, urokinase plasminogen activator; Urokinase-type plasminogen activator

Mesh:

Substances:

Year:  2014        PMID: 24648800      PMCID: PMC3956987          DOI: 10.3904/kjim.2014.29.2.176

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  23 in total

Review 1.  The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.

Authors:  V Ellis; C Pyke; J Eriksen; H Solberg; K Danø
Journal:  Ann N Y Acad Sci       Date:  1992-12-04       Impact factor: 5.691

Review 2.  The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.

Authors:  Daniela Alfano; Paola Franco; Immacolata Vocca; Nadia Gambi; Viviana Pisa; Alessandro Mancini; Mario Caputi; Maria Vincenza Carriero; Ingram Iaccarino; Maria Patrizia Stoppelli
Journal:  Thromb Haemost       Date:  2005-02       Impact factor: 5.249

3.  Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy.

Authors:  Guoqiang Zhang; Heungsoo Kim; Xiaohe Cai; Jesús M López-Guisa; Charles E Alpers; Youhua Liu; Peter Carmeliet; Allison A Eddy
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

4.  Urokinase concentration in the renal artery and vein.

Authors:  S Y Hong; D H Yang; P N Kim
Journal:  Nephron       Date:  1992       Impact factor: 2.847

5.  Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria.

Authors:  A A Eddy; C M Giachelli
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

6.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

Review 7.  Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

Authors:  Michael J Duffy
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

Review 8.  The urokinase plasminogen activator system: role in malignancy.

Authors:  Michael J Duffy
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

9.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.

Authors:  A P Sappino; J Huarte; J D Vassalli; D Belin
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 10.  The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.

Authors:  Ann Gils; Paul J Declerck
Journal:  Thromb Haemost       Date:  2004-03       Impact factor: 5.249

View more
  4 in total

Review 1.  Biomarkers in Primary Focal Segmental Glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy.

Authors:  Aleksandra Musiała; Piotr Donizy; Hanna Augustyniak-Bartosik; Katarzyna Jakuszko; Mirosław Banasik; Katarzyna Kościelska-Kasprzak; Magdalena Krajewska; Dorota Kamińska
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

2.  Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.

Authors:  Yanfeng Zhao; Lijun Liu; Jing Huang; Sufang Shi; Jicheng Lv; Gang Liu; Minghui Zhao; Hong Zhang
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

3.  Urokinase-type plasminogen activator receptor in IgA nephropathy.

Authors:  Shin-Young Ahn; Ho Jun Chin
Journal:  Korean J Intern Med       Date:  2014-02-27       Impact factor: 2.884

4.  Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.

Authors:  Hong Jiang; Ludan Liang; Jing Qin; Yingying Lu; Bingjue Li; Yucheng Wang; Chuan Lin; Qin Zhou; Shi Feng; Shun H Yip; Feng Xu; En Yin Lai; Junwen Wang; Jianghua Chen
Journal:  Oncotarget       Date:  2016-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.